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Patients in whom the standard of care has failed or who have uncommon tumors for
which no standard of care exists are often treated with drugs selected based on the
physician’s best guess. The rate of success for this method is generally low. With the
advent of fast, affordable tumor proﬁling technologies, and a growth in the understanding
of predictive biomarkers, it is now possible to identify drugs potentially associated with
clinical beneﬁt for such patients. We present the Caris approach to evidence-based tumor
proﬁling and two patients with advanced ovarian and prostate cancer in whom standard of
care had failed and tumor proﬁling identiﬁed an effective treatment schedule. To establish
Caris Molecular IntelligenceTM (CMI), over 120,000 clinical publications were screened
and graded to characterize the predictive value of biomarkers that form the panel of tests.
CMI includes multiple technologies to measure changes in proteins, ribonucleic acid, and
deoxyribonucleic acid and proprietary software that matches the test results with the
published evidence. The CMI results enable physicians to select drugs that are more likely
to beneﬁt the patients, avoid drugs that are not likely to work, and ﬁnd treatment options
that otherwise would not be considered. Worldwide, over 60,000 cancer patients have
undergone evidence-based tumor proﬁling with CMI. In the cases reported in this article,
CMI identiﬁed treatments that would not have been routinely used in the respective clinical
setting. The clinical outcomes observed help to illustrate the utility of this approach.
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INTRODUCTION
Patients who reach the end of their guidelines-deﬁned treatment
options and are suitable and willing to receive further treatment,
or who present with an uncommon cancer type where treatment
options are limited, are among the most difﬁcult to treat. In such
cases, the treatment decision is based on the individual patient’s
clinical context, physician’s experience and clinical judgment, local
practice guidelines and thepatient’smedical and treatment history.
While the overall rate of success for cancer drug treatment has been
estimated at 35% (Jackson, 2009), treatment for these patients is
less effective, e.g., the response rate to therapy in patients meet-
ing the inclusion criteria for early clinical studies is around 10%
(Olmos et al., 2012).
Advances in the discovery of prognostic and predictive
biomarkers can provide oncologists with vital information which
helps to stratify their patients for risk of tumor progression
and identify potentially beneﬁcial therapeutic agents based on
biomarker expression patterns. For example, lung cancer has tra-
ditionally been viewed as difﬁcult to treat and associated with
poor prognosis. The last 5 years has seen epidermal growth fac-
tor receptor (EGFR) mutation testing become standard of care for
selection of treatment with erlotinib or geﬁtinib in non-small cell
lung cancer (NSCLC). Many companion diagnostics are now part
of the approved drug label and clinical guidelines indicate which
speciﬁc biomarker should be assessed in a consistent manner in
all patients prior to treatment selection in certain tumor types
in order to identify a deﬁned subgroup for which the respective
treatment is indicated.
While many new drugs received regulatory approval together
with companion diagnostics in a limited, often lineage speciﬁc,
clinical setting, the biological principles governing cancer growth
can often be extrapolated to other indications as well. One exam-
ple is the utility of human EGFR 2 (HER2)-directed treatments
for patients with lung cancer that have a HER2 (encoded by the
ERBB2 gene) mutation. While this occurs in fewer than 2% of all
patients with lung cancer HER2-directed targeted treatments led
to disease control in 82% of patients with HER2 mutations (Maz-
ières et al., 2013). This shows that for a patient with no available
standard treatment options molecular proﬁling can reveal speciﬁc
biomarkers that are associated with beneﬁt from drugs that would
typically not have been considered for treatment.
As the majority of individual mutations or other molecu-
lar changes are usually rare, a comprehensive proﬁling increases
the chance that a valuable alteration is identiﬁed. Comprehen-
sive proﬁling delivers all relevant information at once, rather
than taking a stepwise approach where tests are ordered one by
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one dependent on the outcome of single biomarker results. This
saves valuable time for the patient and confers an important
advantage because the comprehensive overview of the patient’s
molecular changes provides the best support for rational treatment
decisions.
Over recent years, tumor proﬁling has become a standard in
many large university centers. Tsimberidou et al. (2012) pub-
lished how tumor proﬁling guided recruitment of patients into
clinical trials with targeted drugs at the MD Anderson Cancer
Center. Patients enrolled in studies that required a matching
genetic aberration had a clinical response rate of 27% whereas
only 5% of patients that could not be assigned to a trial based
on molecular proﬁling responded (Tsimberidou et al., 2012). In
a similar approach undertaken at the Princess Margaret Cancer
Centre in Toronto, six of twenty-one patients (29%) enrolled
into ongoing clinical trials with a therapy matched to a genetic
aberration had a conﬁrmed partial response (Bedard et al., 2013).
Both of these groups employed large, cross-functional teams
of experts to interpret the results from molecular testing. The
ability to dedicate experienced teams to guide tumor proﬁling-
directed treatment is beyond the capabilities of most community
practices. Therefore alternative methods had to be developed to
allow patient’s access to reliable and actionable tumor proﬁling
results.
CMI: AN EVIDENCE-BASED APPROACH OF TUMOR
PROFILING FOR CLINICAL DECISION-MAKING
Caris Life Sciences started to offer evidence-based molecular pro-
ﬁling over 8 years ago. The approach taken has been constantly
reﬁned, resulting in a service which is adapted to the latest scien-
tiﬁc knowledge. Caris Molecular IntelligenceTM (CMI) supports
physicians in implementing actionable results from comprehen-
sive tumor proﬁling in their routine practice. CMI is performed
in a high-throughput laboratory that has been customized to
accommodate large numbers of specimens for testing on mul-
tiple technology platforms. Comprehensive molecular testing is
coupled with an evidence-based proprietary algorithm that trans-
lates complex biomarker results into a table of drugs that may
provide beneﬁt or lack of beneﬁt for that patient. Caris has
received accreditation from Clinical Laboratory Improvement
Amendments (CLIAs), as well as an extensive list of certiﬁ-
cations from the state of New York. Caris also has recently
obtained the molecular proﬁling industry’s ﬁrst-ever accredita-
tion to the International Standards Organization (ISO) 15189:
2012 “Medical laboratories – Requirements for quality and com-
petence,” by the American Association for Laboratory Accredita-
tion (A2LA). The CMI service provides each treating physician
with the relevant biomarker testing and current expert inter-
pretation needed to make clinical treatment decisions for each
patient.
The CMI service uses a variety of established technology
platforms to measure a panel of carefully selected biomark-
ers including immunohistochemistry (IHC), ﬂuorescent in situ
hybridization (FISH), polymerase chain reaction (PCR), and
direct gene sequencing. Taking an approach that is not reliant
on a single technology is critical to perform clinically relevant
biomarker testing. Proteins, gene expression, mutations, and gene
rearrangements can all have utility as predictive biomarkers. For
example, of the 93.5% of compounds predicted to be beneﬁcial
which were identiﬁed, 87.2% of them were driven by IHC and
ISH results, 12.6% by IHC, ISH, and NGS results, and 0.2% driven
by NGS results alone. Therefore, an assessment of the molecular
proﬁle of a tumor with just one technology will miss potential
therapeutic options for the patient.
To keep the biomarker panel current, an ongoing review of
the medical literature is performed to review the evidence of
predictive associations of biomarkers with available therapeutics.
The interpretation of the biomarker evidence is under the gov-
ernance of a cross-functional group comprised of oncologists,
molecular geneticists, pathologists, and research scientists. All
biomarkers tested in the CMI service are included based on the
strength of their supporting evidence according to a version of
the United States Preventative Services Task Force (USPSTF) level
of evidence methodology adapted from Harris et al. (2001). The
content of each scientiﬁc paper is appraised for study design,
study validity, and applicability of the biomarker in drug selec-
tion. Today, over 95% of drug/biomarker associations included
in the service are supported by level 1 (randomized, controlled
trials or meta-analyzes) or level 2 (non-randomized, controlled
trials, single arm or cohort/case-control analytic studies) evi-
dence. The evidence system used by Caris allows the service
to evolve in response to new clinical data. As new markers are
identiﬁed and vetted, they can be added to the panel quickly.
An overview of the evidence process for CMI is shown in
Figure 1.
The CMI report aligns the molecular proﬁle of the patient’s
tumor to relevant therapeutic agents associated with potential
beneﬁt or potential lack of beneﬁt for the purpose of serving
as a decision support aid for the treating physician. The report
results are provided to the treating physician and supported by
the relevant references from the peer-reviewed literature as deter-
mined by the evidence review process. The report also enables the
treating clinician to review in detail the biomarker testing that has
been performed, as well as link directly to the clinical evidence
supporting the biomarker-drug association.
CLINICAL EVIDENCE SUPPORTING USE OF CMI
A manuscript has been published with a number of independent
accompanying abstracts which have reported how CMI was used
in clinical practice. The Bisgrove study (Von Hoff et al., 2010)
was the ﬁrst clinical trial to assess the use of a multi-platform
approach to molecular proﬁling to identify treatment targets in
patients with refractory cancers. In this study, patients were pro-
ﬁledwith theCMI panel and physicians chose a treatment regimen
based on the results. Clinical beneﬁt was deﬁned as a 30% increase
in progression-free-survival (PFS) with molecularly guided treat-
ments, compared to the PFS under the most recent prior regimen.
The majority of patients had molecularly identiﬁable targets and
18 of 66 patients (27%) treated on the basis of molecular proﬁling
derived clinical beneﬁt. A recent study in patients with refractory
breast cancer showed that tumor proﬁling resulted in a revision
of the original treatment decision for all patients. Tumor proﬁl-
ing based therapy resulted in a clinical beneﬁt in 52% of heavily
pretreated patients (Jameson et al., 2013). A review of all patients
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FIGURE 1 | Generating Molecular Intelligence: an extensive literature
review is performed by a multi-disciplinary review team, which
examines new research and relevant research, and grades it based on
US PreventativeTask Force methodology in the context of the
biomarkers revealed through the profiling services.The output from this
evidence review forms the basis of a proprietary software package which is
used to translate the results of comprehensive biomarker testing to a
clinically actionable report, providing physicians with meaningful biomarkers,
actionable drug associations, and relevant clinical trials for their individual
patient.
treated in a single center in Australia resulted in clinical and sur-
vival beneﬁts in over half of the patients and conﬁrmed the role of
molecular proﬁling in a clinical practice setting (Dean andWallace,
2013). Though preliminary evidence supports clinical utility, the
degree to which CMI improves patient outcomes has not yet been
demonstrated conclusively. Further evaluations of the approach
are currently ongoing.
CASE STUDY: RESPONSE TO PEMETREXED IN A PATIENT
WITH METASTATIC PROSTATE CANCER
A 63-year-old patient was diagnosed with metastatic prostate can-
cer in 2006 with a Gleason score of 9 and involvement of the
pelvic lymph nodes. The patient initially received radiation ther-
apy to the pelvis and the prostate followed by treatment with
gonadotropin-releasing hormone (GnRH) analogs. After 4 years
the disease progressed and metastasized to the bones, lung, and
liver. Treatment with bisphosphonates, sipuleucel-T, abiraterone,
enzalutamide, docetaxel, and cabazitaxel did not stop progression.
The disease could never be controlled except for short transient
partial responses under docetaxel and abiraterone. Embolization
of the left liver lobe resulted in temporary local pain relief and
as a last resort, the patient received carboplatin with etoposide,
which resulted in a transient partial response followed by rapidly
progressive disease.
As all guideline-recommended treatment options had failed,
it was decided to perform CMI tumor proﬁling. At this time,
the patient had extensive liver metastases with underlying cir-
rhosis, which caused considerable pain. He was wheelchair
bound and unable to walk with an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 3, approaching 4.
Within 6 weeks, his prostate speciﬁc antigen (PSA) had risen
from 84 ng/ml to 177 ng/ml and lactate dehydrogenase (LDH)
levels had risen from 569 to 2196 IU/L. All signs and symptoms
pointed to a rapidly progressive decline of the patient’s general
condition.
The CMI report indicated that the tumor was not express-
ing thymidylate synthase (TS), a protein involved in generation
of critical components for DNA synthesis and repair pathways.
Published level II evidence from a study of 268 patients with
advanced NSCLC who received treatment with pemetrexed after
prior chemotherapy found that patients with low TS expres-
sion had a longer median PFS compared to those with high TS
expression (Chen et al., 2011). The CMI report associated low
TS expression with tumor sensitivity to ﬂuoropyrimidines and
other folate analogs with potential beneﬁt from 5-ﬂuorouracil,
capecitabine or pemetrexed. Therefore, it was decided to begin
treatment with single agent pemetrexed at the end of September
2013 based on the physician’s choice. The patient’s general
www.frontiersin.org April 2014 | Volume 5 | Article 76 | 3
Russell et al. Utility of clinically actionable biomarkers
condition improved rapidly and the intense right upper quadrant
pain resolved completely. Within 5 weeks of starting peme-
trexed treatment, a computed tomography (CT) scan showed
decrease in size of multiple liver metastases (Figure 2). The tumor
marker PSA dropped to 5.1 ng/mL and LDH returned to nor-
mal (423 IU/L). The patient can now care for himself and his
ECOG performance status is 1. The treatment has been toler-
ated exceptionally well and no further admissions to the hospital
became necessary. After 4 months, at this time of this report,
the patient continues to receive 3 weekly cycles of pemetrexed,
PSA (7.5 ng/mL) and LDH (539 IU/L) are indicating a continued
response.
CASE STUDY: RESPONSE TO CETUXIMAB AND IRINOTECAN
IN A PATIENT WITH METASTATIC OVARIAN CANCER
A 49-year-old woman was diagnosed with stage IV ovarian can-
cer in August 2009 after feeling abdominal pain. A CT scan
revealed that she had a mass in her right ovary, which was diag-
nosed as a mixed high grade serous and endometrioid carcinoma.
Surgery conﬁrmed metastatic disease and the patient began stan-
dard treatment with a combination of intraveneous paclitaxel and
carboplatin and intraperitoneal docetaxel/cisplatin. During the
time on treatment, the patient had a partial response; her cancer
antigen 125 (CA-125) level dropped from 475 to 70 U/mL but did
not return to normal levels (less than 35 U/mL). A laparotomy
revealed no obvious tumor masses but the persisting elevation of
CA-125 indicated residual disease.
As the standard treatments had failed a portion of the initial
biopsy material was sent for CMI testing to identify additional
treatment options. Based on the ﬁndings of the report, the patient
was treated with doxorubicin followed by topotecan but both
treatments had to be discontinued due to intolerable toxicities.
Doxorubicin was selected based on overexpression of topoiso-
merase 2A (TOP2A), which has been linked with level II evidence
to doxorubicin response in breast cancer (Durbecq et al., 2004).
FIGURE 2 | CT scans before (A,C) and 5 weeks after initiation of
treatment with pemetrexed (B,D) show decrease in size of metastases
and liver sclerosis and ascites due to previous embolization.
In patients with ovarian cancer treated with topotecan, tumors
with low or undetectable Topoisomerase 1 (TOPO1) protein
levels had a median time to progression of 4.3 months, com-
pared to 13.2 months in patients with high TOPO1 expressing
tumors (Litzow et al., 2010). Although poorly tolerated, both
treatments resulted in transient decreases in CA-125 to normal
levels.
The CMI report also found overexpression of the EGFR gene
and overexpression of the TOPO1 protein. EGFR gene overexpres-
sion along with high phosphatase and tensin homolog (PTEN)
protein expression indicated potential efﬁcacy from cetuximab,
which is targeting the EGFR receptor (Personeni et al., 2008;
Sartore-Bianchi et al.,2009). Irinotecan causes cell killingbyblock-
ing TOPO1. In addition to the topotecan evidence cited above,
level II evidence in colorectal cancer (CRC) patients treated with
irinotecan-containing adjuvant chemotherapy demonstrated that
there was a signiﬁcant improvement in survival in patients who
expressed TOPO1 compared to those with low TOPO1 expres-
sion (Kostopoulos et al., 2009). These results indicated potential
beneﬁt from cetuximab and irinotecan and combination treat-
ment with these drugs was started in late October 2010. After
2 months, bevacizumab was transiently added to this combina-
tion (based on overexpression of the hypoxia-inducible factor
1-alpha (HIF1A) gene) until it caused toxicity. Within 2 months
of the starting the combination of cetuximab and irinotecan the
patient’s CA-125 level dropped from 64 to 10 and stayed nor-
mal over the course of the ﬁrst 8 months of treatment. Although
an attenuated dose was used, toxicities led to discontinuation
of therapy. After discontinuation of cetuximab and irinotecan
the patient developed progressive disease with pelvic and liver
metastases. The patientwas then put on treatmentwith cyclophos-
phamide, which was not included on the CMI report but resulted
in a transient response. Currently the disease is slowly progres-
sive and the patient is still on cyclophosphamide at an attenuated
dose.
A signiﬁcantly long remission after recurrence is unusual in
ovarian cancer and irinotecan and cetuximab are rarely used in
ovarian cancer. This observation is of signiﬁcant importance as
it justiﬁes further exploration of treatments guided by tumor
proﬁling instead of using histological diagnosis of the tumor alone.
CONCLUSION
Patients with metastatic cancer frequently arrive to a point in their
clinical care when all standard of care options have been tried
and they require further treatment. Although guidelines recom-
mend that these patients enter either clinical trials or palliative
care, they are often ﬁt enough and willing to continue to receive
further cytotoxic treatment. Comprehensive tumor proﬁling can
identify active treatment options, help avoiding treatments which
are likely not active, and ﬁnd treatments that otherwise would
not have been considered. Meaningful integration of the infor-
mation generated by comprehensive biomarker testing requires
cross-functional expertise to aid interpretation and determine
which results are clinically relevant. As this level of support is
rarely accessible, CMI provides a service which helps physicians
to develop evidence-based treatment plans. CMI combines the
results of tumor proﬁling with a thorough assessment of the
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published clinical evidence in a comprehensive report that includes
drugs associated with beneﬁt, lack of beneﬁt as well clinical
trials that may be relevant for the patient. The clinical experi-
ence with tumor proﬁling in routine clinical practice has been
promising.
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